NEW YORK, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces that it has initiated coverage of Cosmos Health Inc. (NASDAQ: COSM).
Cosmos Health Inc., headquartered in Chicago, Illinois is a diversified vertically integrated global health organization that manufactures and distributes medical grade nutritional and medicines through its operating subsidiaries of SkyPharm, Decahedron, CANA Pharmaceutical Laboratories, Cosmofarm Pharmaceuticals, and Zip Doctor. It’s portfolio of proprietary pharmaceutical and nutraceutical brands include Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. The CANA subsidiary is licensed to manufacture pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. COSM also distributes a broad line of pharmaceuticals and parapharmaceuticals that includes branded, generics, and OTC medications to retail pharmacies and wholesale distributors in Greece and the United Kingdom.
The complete 21 - page report is available at https://www.taglichbrothers.com/
Taglich Brothers, Inc. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.
We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Axos Clearing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report, we, our affiliates, any officer, director or stockholder, or any member of their families do not have a position in the stock of the company mentioned in this report. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned in this report and was not a manager or co-manager of any offering for the company within the last three years.
All research issued by Taglich Brothers, Inc. is based on public information. In February 2024, upon execution of the agreement and prior to any research services being provided, the company paid Taglich Brothers a monetary fee of $3,000 representing payment for the first month of research coverage after publication. The second month after publication of the initial report, the company will begin paying Taglich Brothers a monthly monetary fee of $3,000 for the creation and dissemination of research reports for a minimum of twelve months after the date the initiation report is first published.
Contact:
Rick Oh
Taglich Brothers, Inc.
631-757-1500
